VIEKIRA XR Drug Patent Profile
✉ Email this page to a colleague
When do Viekira Xr patents expire, and what generic alternatives are available?
Viekira Xr is a drug marketed by Abbvie and is included in one NDA. There are twenty patents protecting this drug.
This drug has six hundred and eight patent family members in fifty-four countries.
The generic ingredient in VIEKIRA XR is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.
DrugPatentWatch® Generic Entry Outlook for Viekira Xr
Viekira Xr was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 2, 2035. This may change due to patent challenges or generic licensing.
There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIEKIRA XR?
- What are the global sales for VIEKIRA XR?
- What is Average Wholesale Price for VIEKIRA XR?
Summary for VIEKIRA XR
International Patents: | 608 |
US Patents: | 20 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 3 |
Patent Applications: | 22 |
Drug Prices: | Drug price information for VIEKIRA XR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIEKIRA XR |
DailyMed Link: | VIEKIRA XR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIEKIRA XR
Generic Entry Date for VIEKIRA XR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIEKIRA XR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Massachusetts General Hospital | Phase 4 |
Merck Sharp & Dohme Corp. | Phase 4 |
University of Florida | Phase 4 |
US Patents and Regulatory Information for VIEKIRA XR
VIEKIRA XR is protected by twenty US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIEKIRA XR is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIEKIRA XR
Solid antiviral dosage forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
Compositions and methods for treating HCV
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for treating HCV
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
Anti-infective agents and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
Solid pharmaceutical dosage form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Solid pharmaceutical dosage form
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Macrocyclic hepatitis C serine protease inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods for treating HCV
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
Methods for treating HCV
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
Anti-infective agents and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
Macrocyclic hepatitis C serine protease inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR
Methods for treating HCV
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
Methods for treating HCV
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
Solid compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Anti-viral compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Anti-viral compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING OMBITASVIR
Compositions and methods for treating HCV
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR
Anti-infective agents and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR
Solid antiviral dosage forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
Solid antiviral dosage forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
Expired US Patents for VIEKIRA XR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIEKIRA XR
When does loss-of-exclusivity occur for VIEKIRA XR?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
European Patent Office
Patent: 89757
Patent: FORMES GALÉNIQUES ANTIVIRALES SOLIDES (SOLID ANTIVIRAL DOSAGE FORMS)
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 1609195
Patent: Solid antiviral dosage forms
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VIEKIRA XR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 5902123 | ⤷ Sign Up | |
Croatia | P20140493 | ⤷ Sign Up | |
Hungary | E039719 | ⤷ Sign Up | |
Japan | 5834085 | ⤷ Sign Up | |
Portugal | 2468286 | ⤷ Sign Up | |
European Patent Office | 3438106 | COMPOSÉS ANTIVIRAUX (ANTI-VIRAL COMPOUNDS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIEKIRA XR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2692346 | PA2017033 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
2692346 | 1790050-7 | Sweden | ⤷ Sign Up | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728 |
2692346 | PA2017033,C2692346 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
2692346 | 132017000122534 | Italy | ⤷ Sign Up | PRODUCT NAME: PIBRENTASVIR, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(MAVIRET); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1213, 20170728 |
2692346 | C20170036 00243 | Estonia | ⤷ Sign Up | PRODUCT NAME: PIBRENTASVIIR;REG NO/DATE: EU/1/17/1213 28.07.2017 |
2340029 | 92667 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PARITAPREVIR, OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX). FIRST REGISTRATION: 20150119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |